Startups Directory

SBS (Smart Brake Lighting System) is a patented automotive safety technology that introduces dynamic rear-light signaling during soft-braking scenarios, improving driver reaction time and reducing rear-end collisions. The system is fully aligned with the latest UNECE regulatory framework and protected by a strong global IP portfolio. SBS is designed for immediate OEM and Tier-1 integration, targeting 2026–2027 vehicle programs in Europe and globally.

SBS (Smart Brake Lighting System) is a patented automotive safety technology that introduces dynamic rear-light signaling during soft-braking scenarios, improving driver reaction time and reducing rear-end collisions. The system is fully aligned with the latest UNECE regulatory framework and protected by a strong global IP portfolio. SBS is designed for immediate OEM and Tier-1 integration, targeting 2026–2027 vehicle programs in Europe and globally.

SBS Smart Brake Lighting delivers a direct, measurable impact on road safety and societal well-being. Rear-end collisions are among the most frequent traffic accidents worldwide, causing injuries, congestion, and significant economic and social costs. A major contributing factor is delayed driver reaction due to insufficient communication of vehicle deceleration, especially during soft-braking events. By enabling earlier and more intuitive visual communication of deceleration: SBS reduces reaction times of following drivers Lowers rear-end collision risk, particularly in urban and high-traffic environments Improves safety for vulnerable road users by smoothing traffic flow and reducing sudden braking chains Supports the safe deployment of EVs and ADAS, where regenerative braking is often not clearly signaled At a systemic level, SBS: Aligns technology with new UNECE regulations, accelerating safer standards adoption Contributes to Vision Zero and road-safety policies Reduces societal costs related to accidents, healthcare, insurance claims, and traffic congestion In summary, SBS transforms rear lighting from a passive indicator into an active safety communication system, delivering benefits not only to drivers and OEMs, but to society as a whole.

We are seeking €1.5–2.0 million in this round. This is a strategic bridge round, not a long-term dilution round. The funds will be used to: Finalize regulatory, IP, and legal readiness post-UNECE WP.29 Support OEM and Tier-1 technical validations for 2026–2027 programs Strengthen our patent enforcement and transaction readiness (licensing / acquisition) Given the current stage — with regulatory approval achieved and Tier-1 acquisition discussions underway — this round is designed to maximize value and optionality, not to fund long product development cycles.

This round is structured as a bridge round to support final regulatory closure, IP strengthening, and strategic transaction execution with Tier-1 automotive suppliers.

We design new optical fiber sensor systems optimized for structural monitoring. We also offer monitoring engineering services, formation and advice for the industries.

We design new optical fiber sensor systems optimized for structural monitoring. We also offer monitoring engineering services, formation and advice for the industries.

A deeper knowledge about the structural condition of different elements, such as road condition, precise machine tooling of critical parts (plane engines...), stud bolts of an aerogenerator, etc. has important impact on the safety and security of the users and assets.

€300.000

€300.000

Empowering chronic care through remote monitoring, clinical data platforms, and artificial intelligence. Monitoring Life has developed Sensocor ML, the world’s first patented portable multisensor integrating ECG, PCG, and PPG that, in just 30 seconds resting on the patient’s chest, captures data and sends it to the cloud for analysis and visualization by the physician.

Empowering chronic care through remote monitoring, clinical data platforms, and artificial intelligence. Monitoring Life has developed Sensocor ML, the world’s first patented portable multisensor integrating ECG, PCG, and PPG that, in just 30 seconds resting on the patient’s chest, captures data and sends it to the cloud for analysis and visualization by the physician.

Our technology delivers a positive societal impact by improving heart failure care across all key stakeholders. For clinicians, it provides reliable, clinically meaningful information that reduces workload and supports better decision-making. For patients, it enables early detection of decompensations from home, leading to fewer hospitalizations and medical visits, and easing the burden on both patients and their families. For public and private healthcare systems and insurers, it contributes to greater sustainability through cost savings, reduced care burden, lower environmental impact, and improved patient experience. By shifting heart failure management from reactive, hospital-based care to proactive, home-based monitoring, our technology supports a more efficient, patient-centered, and sustainable healthcare system.

The investment round comprises two independent options: €2M for the European market and €6M for the U.S. market. This capital will be used to bring Sensocor ML to market and scale it as a unique eHealth solution. Funds will be strategically allocated to the main value drivers, including AI development (20%), clinical studies (20%), and the development of a global digital platform (20%), ensuring strong performance, clinical validation, and scalability. Additional investment will support manufacturing (10%), marketing and sales (15%), and human resources (15%), enabling efficient production, market adoption, and team growth. In the U.S. pathway, the investment also covers FDA Class IIa clearance and market placement, ensuring regulatory readiness and successful commercialization.

The total size of the investment round depends on the selected market entry path: €2M for the European market or €6M for the U.S. market.

: Bioactive Surfaces belongs to a group of four companies with headquarters in the Scientific Park of Madrid, Spain. Our companies pioneer advanced biotechnology, biomaterials, and functionalization technologies, cellular and molecular therapies, tissue engineering, and regenerative medicine. Our products include molecular therapies for ischemic stroke and age-related macular degeneration (both of them entering clinical trials), retina-on-chip platforms for drug screening, adaptive drug delivery systems, biofunctionalized prostheses, spider-like 3D tissue bioprinters, and precision AFM tips. We are fast, highly competent and efficient, capable of delivering cutting-edge solutions under tight timelines. With extensive experience in EU projects (e.g., at the present we coordinate the Pathfinder ISOS & THOR projects).

: Bioactive Surfaces belongs to a group of four companies with headquarters in the Scientific Park of Madrid, Spain. Our companies pioneer advanced biotechnology, biomaterials, and functionalization technologies, cellular and molecular therapies, tissue engineering, and regenerative medicine. Our products include molecular therapies for ischemic stroke and age-related macular degeneration (both of them entering clinical trials), retina-on-chip platforms for drug screening, adaptive drug delivery systems, biofunctionalized prostheses, spider-like 3D tissue bioprinters, and precision AFM tips. We are fast, highly competent and efficient, capable of delivering cutting-edge solutions under tight timelines. With extensive experience in EU projects (e.g., at the present we coordinate the Pathfinder ISOS & THOR projects).

By enabling better-integrated implantable devices and prostheses, Bioactive Surfaces will help to achieve safer and more effective medical technologies. rThAB™-based biofunctionalization will allow advanced implant performance, and long-term device reliability, ultimately leading to better patient outcomes, reduced complications, and accelerated innovation in medical devices and regenerative technologies.

2.0 million EUROs On February 2026 we will start implanting rThAB™-biofunctionalized prostheses in human patients in a public Hospital in Spain. This money will be employed to accelerate the introduction of our technology in the clinic.

5.0 million EUROs

Omnia Mater belongs to a group of four companies with headquarters in the Scientific Park of Madrid, Spain. Our companies pioneer advanced biotechnology, biomaterials, and functionalization technologies, cellular and molecular therapies, tissue engineering, and regenerative medicine. Our products include molecular therapies for ischemic stroke and age-related macular degeneration (both of them entering clinical trials), retina-on-chip platforms for drug screening, adaptive drug delivery systems, biofunctionalized prostheses, spider-like 3D tissue bioprinters, and precision AFM tips. We are fast, highly competent and efficient, capable of delivering cutting-edge solutions under tight timelines. With extensive experience in EU projects (e.g., at the present we coordinate the Pathfinder ISOS & THOR projects).

Omnia Mater belongs to a group of four companies with headquarters in the Scientific Park of Madrid, Spain. Our companies pioneer advanced biotechnology, biomaterials, and functionalization technologies, cellular and molecular therapies, tissue engineering, and regenerative medicine. Our products include molecular therapies for ischemic stroke and age-related macular degeneration (both of them entering clinical trials), retina-on-chip platforms for drug screening, adaptive drug delivery systems, biofunctionalized prostheses, spider-like 3D tissue bioprinters, and precision AFM tips. We are fast, highly competent and efficient, capable of delivering cutting-edge solutions under tight timelines. With extensive experience in EU projects (e.g., at the present we coordinate the Pathfinder ISOS & THOR projects).

By making high-precision bioprinting more accessible, the company supports innovation in regenerative medicine, drug discovery, and personalized healthcare. Omnia Mater’s technologies accelerate the development of artificial tissues and advanced biological models, reducing reliance on animal testing and improving the predictability of biomedical research.

0.8 million EUROs Initial investment aimed at industrializing the THOR-X Bioprinter.

2.5 million EUROs

Silk Biomed belongs to a group of four companies with headquarters in the Scientific Park of Madrid, Spain. Our companies pioneer advanced biotechnology, biomaterials, and functionalization technologies, cellular and molecular therapies, tissue engineering, and regenerative medicine. Our products include molecular therapies for ischemic stroke and age-related macular degeneration (both of them entering clinical trials), retina-on-chip platforms for drug screening, adaptive drug delivery systems, biofunctionalized prostheses, spider-like 3D tissue bioprinters, and precision AFM tips. We are fast, highly competent and efficient, capable of delivering cutting-edge solutions under tight timelines. With extensive experience in EU projects (e.g., at the present we coordinate the Pathfinder ISOS & THOR projects).

Silk Biomed belongs to a group of four companies with headquarters in the Scientific Park of Madrid, Spain. Our companies pioneer advanced biotechnology, biomaterials, and functionalization technologies, cellular and molecular therapies, tissue engineering, and regenerative medicine. Our products include molecular therapies for ischemic stroke and age-related macular degeneration (both of them entering clinical trials), retina-on-chip platforms for drug screening, adaptive drug delivery systems, biofunctionalized prostheses, spider-like 3D tissue bioprinters, and precision AFM tips. We are fast, highly competent and efficient, capable of delivering cutting-edge solutions under tight timelines. With extensive experience in EU projects (e.g., at the present we coordinate the Pathfinder ISOS & THOR projects).

Affecting over 270 million people combined, ischemic stroke and AMD impose a staggering global economic burden exceeding $900 billion annually through lost productivity and high clinical costs. Current therapeutic options remain critically inadequate, as the extremely narrow emergency window for stroke and the repetitive, invasive nature of chronic AMD injections fail to prevent irreversible disability and blindness for the majority of patients. Social Impact: Ischemic stroke is the 3rd leading cause of combined death and disability globally, accounting for over 160 million disability-adjusted life years (DALYs) lost. AMD is responsible for approximately 8.7% of global blindness and is the leading cause of irreversible vision loss in individuals over age 60 in high-income countries.

Contact the company

Contact the company

We develop low-cost advanced carbon nanomaterials for electrochemical applications in batteries and supercapacitors, using waste from the agri-food industry.

We develop low-cost advanced carbon nanomaterials for electrochemical applications in batteries and supercapacitors, using waste from the agri-food industry.

This project valorizes agri-food residues into advanced carbonaceous materials including ultra-high surface area activated carbons, tailored mesoporous carbons, and carbon dots - fully aligned with EU sustainability policies. It supports the Waste Framework Directive and the EU Circular Economy Action Plan by transforming residues into secondary raw materials. By reducing reliance on imported graphite and carbons, it reinforces EU strategic autonomy under the Critical Raw Materials Act. The project fosters Rural Development by sustainably valorizing biomass, creating local jobs in collection, conditioning, and logistics. It promotes Upskilling in Green and Circular Technologies, in line with CAP and ESF+. It helps retain population, diversify incomes, and strengthen territorial cohesion, ensuring an inclusive Green Transition.

375.000€

750.000€

At Umibots we develop autonomous and electric robotics for urban and beach cleaning.

At Umibots we develop autonomous and electric robotics for urban and beach cleaning.

It will improve cleanliness and quality of life in cities, reducing the waste collection taxes paid by citizens.

750,000 USD

750,000 USD

Green hydrogen is key to the energy transition, but its high flammability demands reliable, fast, and efficient detection systems. H2-DETECTOR is a startup born in the Department of Applied Physics at the Autonomous University of Madrid, the result of more than 10 years of collaborative research on hydrogen and two-dimensional materials. Our technology is based on next-generation sensors made with dichalcogenides and functionalized graphene, capable of detecting hydrogen quickly, selectively, and with high sensitivity, overcoming the limitations of conventional sensors. The devices operate over a wide temperature range of 0 to 200 °C, with low power consumption, humidity resistance, reduced cost, and potential for industrial scaling, contributing to a safer and more sustainable hydrogen deployment.

Green hydrogen is key to the energy transition, but its high flammability demands reliable, fast, and efficient detection systems. H2-DETECTOR is a startup born in the Department of Applied Physics at the Autonomous University of Madrid, the result of more than 10 years of collaborative research on hydrogen and two-dimensional materials. Our technology is based on next-generation sensors made with dichalcogenides and functionalized graphene, capable of detecting hydrogen quickly, selectively, and with high sensitivity, overcoming the limitations of conventional sensors. The devices operate over a wide temperature range of 0 to 200 °C, with low power consumption, humidity resistance, reduced cost, and potential for industrial scaling, contributing to a safer and more sustainable hydrogen deployment.

Technology that protects: Innovation and safety in hydrogen

N/A

N/A